RIGL
Rigel Pharmaceuticals, Inc.
RIGL's fundamentals are mixed, but it looks cheap: trading at 2.8x earnings, less than half its usual 6.5x. Analysts expect earnings growth.
RIGL Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Strong | |
| Strong | |
| Strong |
RIGL's profitability, cash flow and balance sheet are currently strong, but its revenue is under pressure.
RIGL PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 2x | $31.38 | -31% |
| Current | 2.8x | $45.69 | — |
| Fair | 6.3x | $102 | +122% |
| Forward | 13x | $45.69 | — |
| Expensive | 20x | $329 | +620% |
Historical ranges are pointers, not guarantees.
RIGL's PE is in its cheap range at 2.8x. On analysts' estimates for next year's earnings, today's price would be 13x, in its expensive range.
RIGL Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Growth | |
| Strong growth | |
| Strongly weakening | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for RIGL, but weaker profitability.
RIGL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.51 | -78% |
| Q3 2026 | $16.08 | +159% |
| Q2 2026 | $16.89 | +209% |
| Q1 2026 | $19.29 | +810% |
| Q4 2025 | $19.48 | +1868% |
| Q3 2025 | $6.22 | +2492% |
| Q2 2025 | $5.46 | +$6.22 |
| Q1 2025 | $2.12 | +$3.22 |
| Q4 2024 | $0.99 | +$2.39 |
RIGL's earnings per share have climbed steadily: $16.08 over the past year, up 159% from the year before, and higher year over year for 15 quarters in a row.
RIGL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $80.9M | +16% |
| Q2 2026 | $78.7M | -23% |
| Q1 2026 | $58.8M | +10% |
| Q4 2025 | $69.8M | +21% |
| Q3 2025 | $69.5M | +26% |
| Q2 2025 | $101.7M | +176% |
| Q1 2025 | $53.3M | +81% |
| Q4 2024 | $57.6M | +61% |
RIGL's revenue is recovering but still below its 2025 peak: $81M last quarter, up 16% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 21% | -20 points |
| Q2 2026 | 30% | -30 points |
| Q1 2026 | 20% | -3.7 points |
| Q4 2025 | 33% | +4.3 points |
| Q3 2025 | 41% | +16 points |
| Q2 2025 | 60% | +59 points |
| Q1 2025 | 24% | +48 points |
| Q4 2024 | 29% | +23 points |
RIGL's operating margin was 21% last quarter, down 20 points from the same quarter a year ago.
RIGL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $34.6M | +44% |
| Q2 2026 | $30.7M | +0.4% |
| Q1 2026 | $2.7M | +$3.6M |
| Q4 2025 | $22M | +52% |
| Q3 2025 | $24M | +11% |
| Q2 2025 | $30.5M | +10012% |
| Q1 2025 | -$893K | +$4.1M |
| Q4 2022 | -$22M | -$2.9M |
RIGL generated $90M in free cash flow over the past year, up 32% from the year before.
RIGL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.4% | +869K shares |
| 1 year | +6.7% | +1.3M shares |
| 3 years | +17% | +3M shares |
| 5 years | +20% | +3.4M shares |
| Available history | +22% | +3.7M shares |
RIGL has 20M diluted shares, up 6.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1M |
| Q2 2026 | $511,000 |
| Q1 2026 | $3.7M |
RIGL Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.6x | Net Cash |
| Q2 2026 | -0.7x | Net Cash |
| Q1 2026 | 0.2x | Very low |
| Q4 2025 | 0.1x | Very low |
| Q3 2025 | 0.1x | Very low |
| Q2 2025 | 0.1x | Very low |
| Q1 2025 | 0.3x | Very low |
| Q4 2024 | 0.1x | Very low |
RIGL has more cash than debt.
RIGL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.3 | Neutral |
| Stochastic | 55.3 | Neutral |
RIGL's weekly RSI is 54 (neutral) and its Stochastic is 55 (neutral).
RIGL PE vs Healthcare Sector
| Metric | RIGL | Sector median | Relative |
|---|---|---|---|
| PE | 2.8x | 26x | 89% below |
| PE % | 30 | 29 | 1 pt above |
RIGL is trading at 2.8x earnings, a 89% discount to the Healthcare sector's median of 26x.
RIGL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $46.9 | 2.6% below |
| 20 week MA | $44.4 | 2.9% above |
| 50 week MA | $38.0 | 20% above |
| 100 week MA | $31.6 | 45% above |
| 200 week MA | $22.4 | 104% above |
RIGL's trend is up, with a small recent dip: it's below only its 8-week average, and 104% above its 200-week average.
RIGL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $20.8 | $36.9 | +77% |
| 2021 | $36.9 | $28.4 | -23% |
| 2022 | $28.4 | $12.3 | -57% |
| 2023 | $12.3 | $14.5 | +18% |
| 2024 | $14.5 | $16.5 | +14% |
| 2025 | $16.5 | $44.0 | +167% |
| 2026 YTD | $44.0 | $45.7 | +3.8% |
RIGL's yearly returns have swung widely, from +167% in 2025 to −57% in 2022. It's up 3.8% so far in 2026.